Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with
advanced non-squamous cell lung cancer. This is a phase IIA pharmacogenomic trial.